JP2011503069A5 - - Google Patents

Download PDF

Info

Publication number
JP2011503069A5
JP2011503069A5 JP2010533115A JP2010533115A JP2011503069A5 JP 2011503069 A5 JP2011503069 A5 JP 2011503069A5 JP 2010533115 A JP2010533115 A JP 2010533115A JP 2010533115 A JP2010533115 A JP 2010533115A JP 2011503069 A5 JP2011503069 A5 JP 2011503069A5
Authority
JP
Japan
Prior art keywords
seq
amino acids
lingo
polypeptide
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010533115A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011503069A (ja
JP5754046B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/012620 external-priority patent/WO2009061500A1/en
Publication of JP2011503069A publication Critical patent/JP2011503069A/ja
Publication of JP2011503069A5 publication Critical patent/JP2011503069A5/ja
Application granted granted Critical
Publication of JP5754046B2 publication Critical patent/JP5754046B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010533115A 2007-11-08 2008-11-10 脱髄を伴う状態の治療におけるlingo−4アンタゴニストの使用 Expired - Fee Related JP5754046B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98649207P 2007-11-08 2007-11-08
US60/986,492 2007-11-08
PCT/US2008/012620 WO2009061500A1 (en) 2007-11-08 2008-11-10 Use of lingo-4 antagonists in the treatment of conditions involving demyelination

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013265573A Division JP2014055186A (ja) 2007-11-08 2013-12-24 脱髄を伴う状態の治療におけるlingo−4アンタゴニストの使用

Publications (3)

Publication Number Publication Date
JP2011503069A JP2011503069A (ja) 2011-01-27
JP2011503069A5 true JP2011503069A5 (cg-RX-API-DMAC7.html) 2012-01-05
JP5754046B2 JP5754046B2 (ja) 2015-07-22

Family

ID=40626097

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010533115A Expired - Fee Related JP5754046B2 (ja) 2007-11-08 2008-11-10 脱髄を伴う状態の治療におけるlingo−4アンタゴニストの使用
JP2013265573A Withdrawn JP2014055186A (ja) 2007-11-08 2013-12-24 脱髄を伴う状態の治療におけるlingo−4アンタゴニストの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013265573A Withdrawn JP2014055186A (ja) 2007-11-08 2013-12-24 脱髄を伴う状態の治療におけるlingo−4アンタゴニストの使用

Country Status (7)

Country Link
US (4) US20110123553A1 (cg-RX-API-DMAC7.html)
EP (1) EP2217697B1 (cg-RX-API-DMAC7.html)
JP (2) JP5754046B2 (cg-RX-API-DMAC7.html)
CN (1) CN101918540B (cg-RX-API-DMAC7.html)
AU (1) AU2008325107B2 (cg-RX-API-DMAC7.html)
CA (1) CA2702630C (cg-RX-API-DMAC7.html)
WO (1) WO2009061500A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1606409T3 (pl) 2003-03-19 2011-02-28 Biogen Ma Inc Białko wiążące receptor Nogo
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
EP1959979A4 (en) * 2005-11-04 2010-01-27 Biogen Idec Inc PROCESS FOR PROMOTING AXON GROWTH AND SURVIVAL OF DOPAMINERGIC NEURONS
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
CA2701189C (en) * 2007-10-11 2017-05-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
FR2958293B1 (fr) 2010-04-01 2014-09-26 Centre Nat Rech Scient Outils pour l'identification de ligands de lingo-1,lingo-2, lingo-3 et lingo-4, et utilisations
JP5859274B2 (ja) 2010-10-29 2016-02-10 アークレイ株式会社 Egfr遺伝子の多型検出用プローブ、増幅用プライマーおよびその用途
US9796780B2 (en) * 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
US10118904B2 (en) 2015-06-05 2018-11-06 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of Demyelinating Diseases
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
GB2568849B (en) 2016-09-01 2022-08-10 Nutrition 21 Llc Magnesium biotinate compositions and methods of use
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) * 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
GB8601597D0 (en) * 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5892019A (en) * 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5413923A (en) * 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5780225A (en) * 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5532351A (en) * 1990-07-12 1996-07-02 Arch Development Corporation Nucleic acid sequences encoding OMGP
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JP3442784B2 (ja) * 1993-11-23 2003-09-02 ジェネンテク,インコーポレイテッド キナーゼ受容体活性化検定法
US5877016A (en) * 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
DE4447588C2 (de) * 1994-05-03 1997-11-20 Omer Osama Dr Dr Med Pflanzliches Arzneimittel zur Behandlung von chronischen und allergischen Rhino-Sino-Bronchitiden
US5516637A (en) * 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
DK0790246T3 (da) * 1994-10-25 2002-03-18 Toyama Chemical Co Ltd Middel til potensering af nervevækstfaktoraktivitet indeholdende 1,2-ethandiolderivat eller salt deraf
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
JP2978435B2 (ja) * 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
ATE486937T1 (de) * 1996-07-12 2010-11-15 Genentech Inc Chimärische heteromultimerische adhesine
NZ333650A (en) * 1996-07-19 2000-02-28 Amgen Inc Analogs of cationic proteins like NT-3 (neurotrophin-3) and BDNF (brain derived neurotrophic factor) that are circulated more readily due to a lower isoelectric point and a lower protein charge relative to the native protein
US6338953B1 (en) * 1996-09-11 2002-01-15 The General Hospital Corporation Expression of an exogenous gene in a mammalian cell by use of a non-mammalian DNA virus having an altered coat protein
US6420140B1 (en) * 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US20070213290A1 (en) * 1996-10-17 2007-09-13 Kingsman Alan J Neurite regeneration
US6593290B1 (en) * 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
RO120148B1 (ro) * 1997-03-14 2005-09-30 Idec Pharmaceuticals Corporation Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ATE310810T1 (de) * 1997-10-24 2005-12-15 Genentech Inc Polypeptid und dafür kodierendes nukeinsäure
US7282482B2 (en) * 1998-04-08 2007-10-16 The Regents Of The University Of California NGF for the prevention of demyelination in the nervous system
US7034132B2 (en) * 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040067490A1 (en) * 2001-09-07 2004-04-08 Mei Zhong Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1189931B1 (en) * 1999-07-02 2006-06-21 Genentech, Inc. Peptide compounds that bind her2
AU6181300A (en) * 1999-07-29 2001-02-19 Helix Research Institute Liver cancer-associated genes
US6680209B1 (en) * 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
US6977723B2 (en) * 2000-01-07 2005-12-20 Transform Pharmaceuticals, Inc. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
WO2001052843A1 (en) * 2000-01-18 2001-07-26 Mcgill University β-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS
PT2857516T (pt) * 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
AU2001266787A1 (en) * 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US7223558B2 (en) * 2001-07-11 2007-05-29 Bristol-Myers Squibb Company Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof
US20050123990A1 (en) * 2001-09-26 2005-06-09 Incyte Corporation Membrane associated proteins
US7309485B2 (en) * 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
WO2003054152A2 (en) * 2001-12-10 2003-07-03 Nuvelo, Inc. Novel nucleic acids and polypeptides
AU2003243139B2 (en) * 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US6919426B2 (en) * 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US7816497B2 (en) * 2002-10-30 2010-10-19 University Of Kentucky Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
PL1606409T3 (pl) * 2003-03-19 2011-02-28 Biogen Ma Inc Białko wiążące receptor Nogo
US7205387B2 (en) * 2003-08-28 2007-04-17 Agency For Science, Technology And Research Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist
AU2005232657B2 (en) * 2004-04-08 2010-12-16 David B. Agus ErbB antagonists for pain therapy
US8353896B2 (en) * 2004-04-19 2013-01-15 The Invention Science Fund I, Llc Controllable release nasal system
PT1776136E (pt) * 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
US20060009288A1 (en) * 2004-07-07 2006-01-12 Devos John A Conveying information to an interrogator using resonant and parasitic radio frequency circuits
EP1789070B1 (en) * 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in neuronal function
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AR054260A1 (es) * 2005-04-26 2007-06-13 Rinat Neuroscience Corp Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos
CA2609077A1 (en) * 2005-05-16 2006-12-28 Mcgill University Lgi, lingo and p75ntr family members: novel modulators of neuronal growth
MX2007015292A (es) * 2005-06-06 2008-02-21 Wyeth Corp Anticuerpos monoclonales anti-trkb y sus usos.
EP2581440B1 (en) * 2005-06-08 2016-03-16 The University of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
SI1904104T1 (sl) * 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090175846A1 (en) * 2005-10-27 2009-07-09 Biogen Idec Ma Inc Oligodendrocyte-Myelin Glycoprotein Compositions and Methods of Use Thereof
US20090175872A1 (en) * 2005-12-02 2009-07-09 Biogen Idec Ma Inc. Treatment of Conditions Involving Demyelination
CN101405297A (zh) * 2006-02-03 2009-04-08 惠氏公司 Lingo-1结构
EP2068866A4 (en) * 2006-07-24 2010-04-07 Biogen Idec Inc METHODS FOR PROMOTING MYELINIZATION, NEURONAL SURVIVAL AND DIFFERENTIATION OF OLIGODENDROCYTES BY ADMINISTERING SP35 OR TRKA ANTAGONISTS
CN103351437A (zh) * 2006-11-17 2013-10-16 诺瓦提斯公司 Lingo结合分子及其制药用途
US8128926B2 (en) * 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
ES2464459T3 (es) * 2008-06-25 2014-06-02 H. Lundbeck A/S Modulación del sistema receptor Trpv:receptor de dominio Vps 10p para el tratamiento del dolor
EP2315779A2 (en) * 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
EP3831954A3 (en) * 2008-11-17 2021-10-13 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics
JP5289986B2 (ja) * 2009-01-20 2013-09-11 株式会社オーディオテクニカ 赤外線送信機

Similar Documents

Publication Publication Date Title
Stoker et al. Recent developments in the treatment of Parkinson's disease
Theis et al. Lentiviral delivery of miR-133b improves functional recovery after spinal cord injury in mice
Turner et al. Antisense peptide nucleic acid‐mediated knockdown of the p75 neurotrophin receptor delays motor neuron disease in mutant SOD1 transgenic mice
US7205387B2 (en) Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist
US20090280058A1 (en) Delivery Of Double-Stranded RNA Into The Central Nervous System
US9809823B2 (en) DNA aptamers for promoting remyelination
CA3173742C (en) Trans-splicing ribozyme specific to apoe4 rna and use thereof
Almutiri et al. Non-viral-mediated suppression of AMIGO3 promotes disinhibited NT3-mediated regeneration of spinal cord dorsal column axons
JP2009518299A5 (cg-RX-API-DMAC7.html)
CN116848128A (zh) 具有非炎症性细胞吞噬作用诱导活性的融合分子
WO2000066068A2 (en) Method for inducing growth and enhancing survival of nervous tissue
WO2021184020A1 (en) Methods of treating neuroinflammation
JP2009538282A5 (cg-RX-API-DMAC7.html)
JP2011504375A (ja) 細胞の中に核酸を導入する医薬組成物及びその方法
AU2022357103A1 (en) Direct transdifferentiation for treatment of neurological disease
US20220033470A1 (en) Compositions Comprising Sortilin-1
US12616712B2 (en) Sting agonist comprising exosomes for treating neuroimmunological disorders
EP4599062A1 (en) Unc13a antisense oligonucleotides and uses thereof
Khalesi et al. 14-3-3ζ protein protects against brain ischemia/reperfusion injury and induces BDNF transcription after MCAO in rat.
AU2015262889A1 (en) Small interfering RNA (siRNA) for the therapy of type 2 (ADO2) autosomal dominant osteopetrosis caused by CLCN7 (ADO2 CLCN7-dependent) gene mutation
CN101084309A (zh) 神经元再生
WO2026048822A1 (ja) Mapt rna配列に基づく新規二本鎖rna及びその利用
Kwon et al. Oncomodulin derived from regeneration-associated macrophages in dorsal root ganglia after preconditioning injury promotes sensory axon regeneration in the spinal cord
CN114369598A (zh) 一种靶向型针对LRRK2的siRNA表达质粒及其在帕金森氏症方面的应用
US20160340690A1 (en) Nov mini-promoters